Updates of Radioiodine Treatment for Graves' Disease
International Journal of Thyroidology
;
: 85-90, 2019.
Article
Dans Coréen
| WPRIM
| ID: wpr-785844
ABSTRACT
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5–50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Iodure de sodium
/
Glande thyroide
/
Maladie de Basedow
/
Incidence
/
Études prospectives
/
Hyperthyroïdie
/
Hypothyroïdie
/
Corée
Type d'étude:
Etude d'incidence
/
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Pays comme sujet:
Asie
langue:
Coréen
Texte intégral:
International Journal of Thyroidology
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS